"While the on-going share buyback should continue to provide support, we believe there is now less scope for future upgrades as the initial recovery impact fades," they say. Liberum keeps a hold rating on the stock, preferring Whitbread and SSP Group in the sector, and a 3,990-pence price target. While the company's consumer-care business did better than expected, its life sciences and performance technologies operations fell short of hopes, Jefferies says. "We expect a small positive share-price response," Jefferies analyst Charles Bentley says in a note, repeating his buy recommendation and 7000p price target. (philip.waller@wsj.com)Contact: London NewsPlus; paul.larkins@wsj.com(END) Dow Jones NewswiresJuly 25, 2023 12:06 ET (16:06 GMT)Copyright (c) 2023 Dow Jones & Company, Inc.

Source: Wall Street Journal July 25, 2023 16:12 UTC